Testimony Before the FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee Regarding Testosterone Undecanoate (Tlando)

January 10, 2018

View as PDF.

In testimony before a meeting of the Food and Drug Administration’s (FDA’s) Bone, Reproductive and Urologic Drugs Advisory Committee, Public Citizen urged the committee to recommend that the FDA reject Lipocine’s oral testosterone undecanoate capsules (Tlando) because of serious safety concerns.